Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS) ...Middle East

LUND, Sweden, Dec. 7, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of care, including...

Hence then, the article about imlifidase demonstrated positive safety tolerability and early efficacy outcomes in 15 hmedides 09 phase 2 trial in guillain barre syndrome gbs was published today ( Thursday 07/12/2023 - 09:28 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS) )

Also on site :

• AI companies are building huge natural gas plants to power data centers. What could go wrong?
• The Trump Dictatorship Is Cracking Up
• Miami lands blue-chip quarterback for 2027 class